Eli Lilly and Company (LLY)

US — Healthcare Sector
Peers: JNJ  BMY  ABBV  PFE  MRK  AMGN  GILD 

Automate Your Wheel Strategy on LLY

With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LLY
  • Rev/Share 54.5268
  • Book/Share 17.633
  • PB 43.4933
  • Debt/Equity 2.4432
  • CurrentRatio 1.3723
  • ROIC 0.2631

 

  • MktCap 723075181200.0
  • FreeCF/Share 0.5421
  • PFCF 1484.1445
  • PE 61.7359
  • Debt/Assets 0.4309
  • DivYield 0.0073
  • ROE 0.7692

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade LLY Erste Group Buy Hold -- -- June 5, 2025
Downgrade LLY HSBC Securities Buy Reduce $1150 $700 April 28, 2025
Initiation LLY Cantor Fitzgerald -- Overweight -- $975 April 22, 2025
Resumed LLY BofA Securities -- Buy -- $997 Dec. 10, 2024
Initiation LLY Bernstein -- Outperform -- $1100 Oct. 17, 2024
Resumed LLY Citigroup -- Buy -- $1060 Sept. 13, 2024

News

Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
LLY
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the value of early intervention and supports a limited duration dosing approach with sustained long-term benefits INDIANAPOLIS , July 30, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI).1 …

Read More
image for news Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Eli Lilly (LLY) Declines More Than Market: Some Information for Investors
LLY
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral

Eli Lilly (LLY) reached $762.95 at the closing of the latest trading day, reflecting a -5.59% change compared to its last close.

Read More
image for news Eli Lilly (LLY) Declines More Than Market: Some Information for Investors
Lilly set for strong quarter after Novo profit warning
LLY
Published: July 29, 2025 by: Reuters
Sentiment: Positive

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook and updates on an experimental obesity drug to gauge the U.S. drugmaker's longer-term health.

Read More
image for news Lilly set for strong quarter after Novo profit warning
The Big 3: OKTA, LLY, ADSK
ADSK, LLY, OKTA
Published: July 25, 2025 by: Schwab Network
Sentiment: Positive

@ProsperTradingAcademy's Charles Moon turns to three names he sees making notable recoveries in their stock price. He talks about the "great upside" Okta Inc. (OKTA) holds, Eli Lilly's (LLY) "technical breakout," and Autodesk's (ADSK) path to reclaim its 52-week high.

Read More
image for news The Big 3: OKTA, LLY, ADSK
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
LLY
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Read More
image for news Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
INSERTING and REPLACING Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
LLY
Published: July 24, 2025 by: Business Wire
Sentiment: Neutral

BRISBANE, Calif.--(BUSINESS WIRE)--Insert updated third paragraph, first sentence of release: Under the terms of the agreement, Gate will receive an upfront payment and equity investment and will be eligible to receive milestone payments upon achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties on global net sales, with a total deal value up to $856 million. The updated release reads: GATE BIOSCIENCE ENTERS INTO A COLLABORATION AND LICENSE AGREE.

Read More
image for news INSERTING and REPLACING Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
A New Obesity Contender From China Targeting Same Receptors As Eli Lilly's Blockbuster
LLY
Published: July 24, 2025 by: Benzinga
Sentiment: Positive

The Chinese drug company is looking to break into the big league for weight-loss treatments after its injection demonstrated sustained weight loss in Phase Three trials

Read More
image for news A New Obesity Contender From China Targeting Same Receptors As Eli Lilly's Blockbuster
Lilly confirms date and conference call for second-quarter 2025 financial results announcement
LLY
Published: July 24, 2025 by: PRNewsWire
Sentiment: Neutral

INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2025 financial results on August 7, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

Read More
image for news Lilly confirms date and conference call for second-quarter 2025 financial results announcement
Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
LLY
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
LLY, NVS
Published: July 20, 2025 by: The Motley Fool
Sentiment: Negative

President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the country.

Read More
image for news Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
Calls of the Day: Eli Lilly and Materion
LLY
Published: July 18, 2025 by: CNBC Television
Sentiment: Neutral

The Investment Committee debate the latest Calls of the Day.

Read More
image for news Calls of the Day: Eli Lilly and Materion
Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet
LLY
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Negative

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Read More
image for news Brokers Suggest Investing in Lilly (LLY): Read This Before Placing a Bet
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
LLY
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive

LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.

Read More
image for news Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
LLY
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Read More
image for news Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
BSX, LLY
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Read More
image for news These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipeline
LLY
Published: July 09, 2025 by: Proactive Investors
Sentiment: Positive

Bank of America on Wednesday reiterated its “Buy” rating and $1,000 price objective on Eli Lilly and Co (NYSE:LLY), ahead of the drugmaker's second-quarter earnings due on August 7, citing durable growth prospects and strong positioning in the obesity and diabetes markets. The bank made only minor adjustments to its revenue and earnings estimates through 2026, driven primarily by higher sales expectations for weight-loss drug Zepbound.

Read More
image for news Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipeline
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
ABBV, JNJ, LLY
Published: July 08, 2025 by: CNBC
Sentiment: Neutral

President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.

Read More
image for news Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
LLY
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Read More
image for news Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
LLY
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Read More
image for news Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?
LLY
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Read More
image for news Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?
CVS drops Lilly's Zepbound
CVS, LLY
Published: July 01, 2025 by: CNBC Television
Sentiment: Negative

CNBC's Angelica Peebles reports on news regarding CVS.

Read More
image for news CVS drops Lilly's Zepbound
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
LLY
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Read More
image for news Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
LLY, NVO
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.

Read More
image for news NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
LLY
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive

Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.

Read More
image for news Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
Lilly declares third-quarter 2025 dividend
LLY
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral

INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025.

Read More
image for news Lilly declares third-quarter 2025 dividend
Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript
LLY
Published: June 23, 2025 by: Seeking Alpha
Sentiment: Neutral

Eli Lilly and Company (NYSE:LLY ) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22, 2025 7:30 PM ET Company Participants Jeffrey Emmick - Vice President of Diabetes Product Development Kenneth L Custer - Executive VP & President of Lilly Cardiometabolic Health Michael Czapar - Director of Investor Relations Ruth Gimeno - Corporate Participant Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexandria Janet Hammond - Wolfe Research, LLC Bryan Russell Dollinger - Leerink Partners LLC, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.

Read More
image for news Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
LLY
Published: June 22, 2025 by: PRNewsWire
Sentiment: Neutral

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS , June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used …

Read More
image for news Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Final Trade: LLY, SHEL, USO, WMT
LLY, WMT
Published: June 20, 2025 by: CNBC Television
Sentiment: Neutral

The final trades of the day with the Fast Money traders.

Read More
image for news Final Trade: LLY, SHEL, USO, WMT
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
LLY
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
LLY
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Neutral

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.

Read More
image for news What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?

About Eli Lilly and Company (LLY)

  • IPO Date 1972-06-01
  • Website https://www.lilly.com
  • Industry Drug Manufacturers - General
  • CEO David A. Ricks
  • Employees 47000

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.